Uterine fibroids, also known as uterine leiomyomas, are the most common tumors affecting the female reproductive tract. These tumors disrupt the function of uterus and causes anemia, excess bleeding, and pelvic discomfort. There are various treatment options available for the treatment of the condition such as drug therapy and surgical procedure.

U.S. uterine fibroids treatment market is estimated to account for US$ 243.5 Mn in terms of value in 2020 and is expected to reach US$ 298.5 Mn by the end of 2027.

U.S. Uterine Fibroids Treatment Market: Drivers

High incidence of uterine fibroids among women is expected to propel growth of the U.S. uterine fibroids treatment market over the forecast period. For instance, according to the study, ‘A US population-based study of uterine fibroids diagnosis incidence, trends, and prevalence: 2005 through 2014’ published in October 2018, the incidence rates for fibroids diagnoses was 240.3 per 10,000 woman-years in 2014 in the age group 45–49 years.

Moreover, availability of effective therapies is also expected to aid in growth of the market. For instance, ulipristal acetate (UPA) is effective in reducing the symptoms due to uterine leiomyomata. UPA is approved for short?term use prior to surgery and longer?term use.

Hysterectomy held dominant position in the U.S. uterine fibroids treatment market in 2019, accounting for 79.0% share in terms of value, followed by myomectomy and endometrial ablation, respectively.

Figure 1. U.S. Uterine Fibroid Treatment Market Share (%), by Value, by Procedure Type, 2019

U.S. Uterine Fibroid Treatment | Coherent Market Insights

U.S. Uterine Fibroids Treatment Market: Restraints

Complications associated with morcellators are expected to hinder growth of the U.S. uterine fibroids treatment market. Laparoscopic power morcellators are used in hysterectomy and myomectomy procedures for the treatment of uterine fibroids. However, power morcellators could cause complications such as metastatic leiomyosarcoma cancer.

Moreover, current treatments for fibroids are mainly surgical and expensive, which is also expected to limit growth of the market.

U.S. Uterine Fibroids Treatment Market: Opportunities

Improved awareness and education regarding uterine fibroids treatment is expected to offer lucrative growth opportunities for players in the market. For instance, the study, ‘Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women’, published in November 2018, concluded that women with fibroids or symptoms suggestive of fibroids experience significant distress that reduces quality of life and that several many women are likely undiagnosed, which increases the need for improved awareness and education.

Moreover, uterine fibroids is a difficult condition to study. However, the burden of the condition is high, which increases the need for rigorous and innovative research related to the condition.

The U.S. uterine fibroids treatment market was valued at US$ 236.7 Mn in 2019 and is forecast to reach a value of US$ 298.5 Mn by 2027 at a CAGR of 3.0% between 2020 and 2027.

Figure 2. U.S. Uterine Fibroids Treatment Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

U.S. Uterine Fibroid Treatment | Coherent Market Insights

Market Trends/Key Takeaways

Use of ulipristal acetate (UPA) may lead to drug?induced liver injury. However, this can be considered as a very rare idiosyncratic event. UPA should not be recommended to patients with liver anomalies or disorders.

The adoption of pharmacologic therapy is high in the U.S. for the treatment of uterine fibroids. For instance, according to the study, ‘Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women’, published in November 2018, 71% of uterine fibroids patients used pharmacologic therapy for symptom relief and 30% underwent surgical or procedural treatment.

U.S. Uterine Fibroids Treatment Market: Competitive Landscape

Major players operating in the U.S. uterine fibroids treatment market include, Blue Endo, Boston Scientific Corporation, CooperSurgical, Inc., KARL STORZ SE & Co. KG, Myovant Sciences (Sumitovant Biopharma Ltd.), Halt Medical, Inc., LiNA Medical USA, Merit Medical Systems, Olympus Corporation, and Richard Wolf GmbH.

U.S. Uterine Fibroids Treatment Market: Key Developments

Major players in the market are focused on R&D to expand their product portfolio. For instance, in April 2020, Sumitovant Biopharma Ltd. announced publication of abstracts from Myovant Sciences regarding the efficacy and safety of relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids, in the journal Obstetrics & Gynecology.

Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in April 2018, CooperSurgical acquired the assets of The LifeGlobal Group and its affiliates, a leading global provider of in-vitro fertilization devices.